Jefferies raised the firm’s price target on Welltower (WELL) to $231 from $210 and keeps a Buy rating on the shares as part of a broader research note previewing 2026 for Healthcare REITs. For Welltower, Jefferies notes that senior housing operating portfolios are setting up for multiple years of outsized growth, while the company also plans to expand their end-to-end tech platform to additional operators this year, enhancing margin expansion.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WELL:
- Welltower price target raised to $232 from $203 at UBS
- Welltower price target raised to $218 from $200 at Wells Fargo
- Welltower price target raised to $200 from $170 at Morgan Stanley
- Welltower price target raised to $260 from $246 at BofA
- Welltower price target raised to $214 from $182 at Scotiabank